A leading solution in target deconvolution and receptor identification
Retrogenix provides the leading solution for receptor and membrane target deconvolution. We specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses.
Retrogenix identifies on behalf of its clients:
Target deconvolution is achieved by screening our clients’ molecules for interactions against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 3500 proteins, this represents the majority of known plasma membrane proteins.
Retrogenix has a rich client portfolio, including many global pharmaceutical / drug discovery companies and several notable academic institutions. We give our commercial clients a competitive advantage by identifying high quality, unexploited drug targets, and helping them to improve success rates at all stages of the drug research and development process.
13/08/2015 | New MedImmune paper: Discovering anti-cancer biologics using primary 3-D phenotypic screening and Retrogenix’s plasma membrane protein array technology. A new paper published in the journal 'Molecular Cancer' describes recent work – led by scientists at MedImmune – to select novel, functional antibodies against primary tumour cells using 3-D phenotypic screening. The Retrogenix... | Read More
Retrogenix will be attending the 21st Annual Biotechnology-Derived Therapeutics: Perspectives on Nonclinical Development Symposium on the 28th, 29th and 30th September in San Diego, USA | Find out more
“…"no doubt" that the breakthrough in identifying EPCR was due to the Retrogenix screening tool” | Read more
Professor Thomas Lavstsen, University of Copenhagen